Gilead, LEO Pharma partner to develop programs for inflammatory diseases
Gilead Sciences said on Saturday that it entered into a partnership with Denmark's LEO Pharma to develop programs to treat ...
Gilead in pact for anti-inflammatory drugs in a deal worth up to $1.7B
Gilead Sciences (NASDAQ:GILD) and Danish pharmaceutical company LEO Pharma on Saturday announced an agreement worth up to ...
Morningstar2d
Gilead Sciences Inc GILD
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.
BioSpace3d
Gilead Continues Diversification Drive With Potential $1.7B Inflammation Pact With LEO
Gilead’s investment will let it assess the therapeutic potential of targeting STAT6, a transcription factor involved in IL-4 ...
Gilead Sciences: Strategic Growth and Optimism Amidst Market Challenges
Jefferies analyst Michael Yee maintained a Buy rating on Gilead Sciences (GILD – Research Report) yesterday and set a price target of ...
Business Wire5d
Gilead and LEO Pharma Enter Into Strategic Partnership to Accelerate Development of Oral STAT6 Program With Potential in Multiple Inflammatory Diseases
Gilead Sciences, Inc. (Nasdaq: GILD) and LEO Pharma today announced a strategic partnership to accelerate the development and ...
Gilead Sciences: Supreme Court Case and New Innovations Drive Buy Rating
Michael Yee, an analyst from Jefferies, maintained the Buy rating on Gilead Sciences (GILD – Research Report). The associated price target ...
STAT9d
Galapagos to split itself into two companies as part of turnaround plan
The beleaguered Belgian firm Galapagos is splitting itself into two companies, with the brandname biotech prioritizing ...
Gilead Sciences (NASDAQ:GILD) Upgraded at Morgan Stanley
Morgan Stanley upgraded shares of Gilead Sciences (NASDAQ:GILD – Free Report) from an equal weight rating to an overweight rating in a research note published on Friday, MarketBeat.com reports. Morgan ...